Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.
Tiga TX has raised $35.5M in total funding. The most recent round was Grant. The last funding was announced in December 2024.
Tiga TX's investors include Advanced Research Projects Agency for Health, BioGeneration Ventures, National Cancer Institute.
Tiga TX is headquartered in Boston, United States.
Tiga TX develops an IgA therapeutic monoclonal antibody platform for the treatment of solid tumors.
Tiga TX is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tiga TX — Funding & Investors." VCBacked, December 18, 2024, https://www.vcbacked.co/company/tiga-tx. Accessed August 14, 2026.
VCBacked. (2024). Tiga TX — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/tiga-tx
{{cite web |title=Tiga TX — Funding & Investors |url=https://www.vcbacked.co/company/tiga-tx |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated